Analysts Set Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) PT at $52.29

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) has earned an average recommendation of “Moderate Buy” from the nine brokerages that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12 month price […]

Leave a Reply

Your email address will not be published.

Previous post Paul Krugman: Trump and Vance learned nothing from Obamacare
Next post Analysts Set Hess Co. (NYSE:HES) Target Price at $171.31